President Lim Juhyun, 'Owner 2nd Generation', Appointed as Head of Strategic Planning at Hanmi Science

Hanmi Science, the holding company of Hanmi Group, announced on the 10th that it has appointed Lim Joo-hyun, president of Hanmi Pharm, as the head of the Strategic Planning Office. President Lim is the eldest daughter of the late Lim Sung-ki, the founder of Hanmi Pharm.

President Lim is responsible for overseeing the establishment of Hanmi Pharm's global strategy. In March of last year, she was also appointed as a director of Spectrum, Hanmi Pharm's U.S. partner company, leading the formulation of global commercialization strategies for key new drugs. In September of last year, Hanmi Pharm's neutropenia treatment 'Rolontis' (U.S. product name Rolvedon) received marketing approval from the U.S. Food and Drug Administration (FDA), and it is known that President Lim played a significant role in this process.

A Hanmi Science official explained, "This personnel appointment is aimed at building a strong management environment to devise a strategy for the 'new 50 years' in celebration of the 50th anniversary of Hanmi Group's founding and to prepare for the leap to a '100-year company.'"

The official added, "Based on the leadership of Chairwoman Song Young-sook and the planning of President Lim Joo-hyun, we will focus on fostering future growth engines at the group level, including innovative new drug research and development (R&D), global business, and digital healthcare."

Lim Juhyun, President of Hanmi Pharm.
[Photo by Hanmi Pharm]

This content was produced with the assistance of AI translation services.